Effective radiotherapy of primary tumors and metastasis with 18F-2-deoxy-2-fluoro-D-glucose in C57BL/6 mice

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 3, 2008, Pages 371-375

  Caridad, Victoria ^a   Arsenak, Miriam ^a   Abad, María Jesús ^a   Martín, Rafael ^b   Guillén, Nilo ^b   Colmenter, Luís Felipe ^c   Taylor, Peter ^a  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b FACULTAD DE CIENCIAS   (Venezuela)

^c Centro Diagnóstico Docente Las Mercedes   (Venezuela)

Author keywords

18F 2 deoxy 2 fluoro D glucose; Metastasis; Mouse; Positron; Radiotherapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; LUNG METASTASIS; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; FLUORODEOXYGLUCOSE F18; GENTIAN VIOLET; HUMANS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIATION ONCOLOGY; RADIOPHARMACEUTICALS;

EID: 46449131923     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.0451     Document Type: Article

References (23)

1. Conti PS, Lilien DL, Hawley K, Keppler J, Grafton ST, Bading JR. PET and [18F]-FDG in oncology: a clinical update. Nucl Med Biol 1996;23:717.
2. McKeehan WL. Glycolysis, glutaminolysis and cell proliferation. Cell Biol Int Rep 1982;6:635.
3. Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D- glucose. J Comput Assist Tomogr 1993;17:582.
4. Moon DH, Maddahi J, Silverman DHS, Glaspy JA, Phelps ME, Hoh CK. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431.
5. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227:764.
6. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750.
7. Moadel RM, Nguyen AV, Lin EY, et al. Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer. Breast Cancer Res 2003;5:R199.
8. Mortimer JE, Taylor ME. Positron-emitting 18F-2-deoxy-2-fluro-D-glucose: potential "hot" new therapy. Breast Cancer Res 2003;5:329.
9. Moadel RM, Weldon RH, Katz EB, et al. Positherapy: targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose. Cancer Res 2005;65:698.
10. Winkelmann CT, Figueroa SD, Rold TL, Volkert WA, Hoffman TJ. Microimaging characterization of a B16-F10 melanoma metastasis mouse model. Mol Imaging 2006;5:105.
11. National Cancer Institute, National Institute of Health. Discovery Services - Screening - DTP Human Tumor Cell Line Screen. Available from: http://dtp.nci.nih.gov/branches/btb/ivclsp.html.
12. Hill HZ, Hill GJ, Miller CF. Radiation and melanoma: response of B16 mouse tumor cells and clonal lines to in vitro irradiation. Radiat Res 1979;80:259.
13. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8:1765.
14. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005;174:7516.
15. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860.
16. Abouzied MM, Crawford ES, Nabi HA. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol 2005;33:145.
17. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972.
18. Eigtved A, Andersson AP, Dahlstrøm K, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000;27:70.
19. Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skarnemark G. Low-energy electron emitters for targeted radiotherapy of small tumours. Acta Oncol 2001;40:602.
20. O'Donoghue JA, Bardies M, Wheldon TE, Sgouros G. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902.
21. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999;19:61.
22. Schiff ND, Ribary U, Moreno DR, et al. Residual cerebral activity and behavioural fragments can remain in the persistently vegetative brain. Brain 2002;125:1210.
23. Blacklock JB, Oldfield EH, Di Chiro G. Effect of barbiturate coma on glucose utilization in normal brain versus gliomas. Positron emission tomography studies. J Neurosurg 1987;67:71.